비타민B3 (나이아시나마이드)

Updated Meta-Analysis on Vitamin Supplementation for Chronic Pruritus: Expanding Evidence Beyond Vitamin D.

1. Int J Mol Sci. 2025 Apr 18;26(8):3840. doi: 10.3390/ijms26083840. Updated Meta-Analysis on Vitamin Supplementation for Chronic Pruritus: Expanding Evidence Beyond Vitamin D. Kuo WH(1), Chang KS(2), Chang MH(3), Hsiao Y(4), Tsai RY(5)(6). Author information: (1)Department of Gastroenterology a

The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis.

2. J Cachexia Sarcopenia Muscle. 2025 Jun;16(3):e13799. doi: 10.1002/jcsm.13799. The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis. Prokopidis K(1), Moriarty F(2), Bahat G(3), McLean J(4), Church DD(5), Patel HP(6)(

The Role of Nicotinamide as Chemo-Preventive Agent in NMSCs: A Systematic Review and Meta-Analysis.

3. Nutrients. 2023 Dec 27;16(1):100. doi: 10.3390/nu16010100. The Role of Nicotinamide as Chemo-Preventive Agent in NMSCs: A Systematic Review and Meta-Analysis. Tosti G(1), Pepe F(1), Gnagnarella P(2), Silvestri F(1), Gaeta A(3)(4), Queirolo P(5), Gandini S(3). Author information: (1)Dermato-O

Bleeding risk in cancer patients treated with sorafenib: A meta-analysis of randomized controlled trials.

4. J Cancer Res Ther. 2018 Dec;14(Supplement):S948-S956. doi: 10.4103/0973-1482.188430. Bleeding risk in cancer patients treated with sorafenib: A meta-analysis of randomized controlled trials. Dai C(1), Zhou F(2), Shao JH(2), Wu LQ(2), Yu X(1), Yin XB(1). Author information: (1)Department of H

Definition of a tolerable upper intake level of niacin: a systematic review and meta-analysis of the dose-dependent effects of nicotinamide and nicotinic acid supplementation.

5. Nutr Rev. 2017 Jun 1;75(6):471-490. doi: 10.1093/nutrit/nux011. Definition of a tolerable upper intake level of niacin: a systematic review and meta-analysis of the dose-dependent effects of nicotinamide and nicotinic acid supplementation. Minto C(1), Vecchio MG(2), Lamprecht M(2), Gregori D(

Safety and efficacy of individualised exercise and NAD(+) precursor supplementation in patients with Friedreich's ataxia in the USA: a single-centre, 2 × 2 factorial, randomised controlled trial.

6. Lancet Neurol. 2026 May;25(5):469-481. doi: 10.1016/S1474-4422(26)00082-7. Safety and efficacy of individualised exercise and NAD(+) precursor supplementation in patients with Friedreich's ataxia in the USA: a single-centre, 2 × 2 factorial, randomised controlled trial. Lin KY(1), Bucha A(1),

The differential impact of three different NAD(+) boosters on circulatory NAD and microbial metabolism in humans.

7. Nat Metab. 2026 Jan;8(1):62-73. doi: 10.1038/s42255-025-01421-8. Epub 2026 Jan 15. The differential impact of three different NAD(+) boosters on circulatory NAD and microbial metabolism in humans. Christen S(1), Redeuil K(1), Goulet L(1), Giner MP(1), Breton I(1), Rota R(1), Frézal A(1), Naz

[Pathogenetic and therapeutic approaches to the correction of neurocognitive disorders in patients with chronic brucellosis].

8. Ter Arkh. 2025 Dec 20;97(11):933-939. doi: 10.26442/00403660.2025.11.203483. [Pathogenetic and therapeutic approaches to the correction of neurocognitive disorders in patients with chronic brucellosis]. [Article in Russian; Abstract available in Russian from the publisher] Shuldyakov AA(1), S

Evaluation of Nicotinamide Riboside in Prevention of Small Nerve Fiber Axon Degeneration and Promotion of Nerve Regeneration.

9. J Peripher Nerv Syst. 2026 Mar;31(1):e70101. doi: 10.1111/jns.70101. Evaluation of Nicotinamide Riboside in Prevention of Small Nerve Fiber Axon Degeneration and Promotion of Nerve Regeneration. Thomas S(1), Ben-Davies R(1), Cetinkaya-Fisgin A(1), Hu X(1)(2), Li X(1), Stewart S(1), Pan B(1),

Rapid and Visible Efficacy of a Dermocosmetic in Acne Patients With Fair Skin Phototypes: Results of a Randomized Split-Face Study.

10. J Cosmet Dermatol. 2026 Jan;25(1):e70641. doi: 10.1111/jocd.70641. Rapid and Visible Efficacy of a Dermocosmetic in Acne Patients With Fair Skin Phototypes: Results of a Randomized Split-Face Study. Queille-Roussel C(1), Odeimi J(2), Broallier M(2), Kerob D(2), Tan J(3). Author information:

Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial.

11. Blood. 2026 Mar 26;147(13):1433-1446. doi: 10.1182/blood.2025029210. Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial. Cortes JE(1), Hughes TP(2), Wang J(3), Kim DW(4), Kim DDH(5), Mayer J(6), Goh YT(7), le Coutre P(8), Et

Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance).

12. ESMO Open. 2025 Dec;10(12):105848. doi: 10.1016/j.esmoop.2025.105848. Epub 2025 Dec 2. Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance). Dercle L(1), Geyer S(2), Nixon AB(3), Inno

Safety and efficacy of niosomal and conventional tranexamic acid/niacinamide vs. hydroquinone creams in melasma: A randomized, double-blind, case-controlled clinical trial.

13. Sci Rep. 2025 Nov 28;15(1):42739. doi: 10.1038/s41598-025-26693-8. Safety and efficacy of niosomal and conventional tranexamic acid/niacinamide vs. hydroquinone creams in melasma: A randomized, double-blind, case-controlled clinical trial. Ghasemiyeh P(1), Haghighi NF(2)(3), Dastgheib L(2)(3

Enhancing Facial Rejuvenation Outcomes With a Novel Retinaldehyde-Based Cream: A Comparative Randomized Intra-Individual Study.

14. J Cosmet Dermatol. 2025 Dec;24(12):e70555. doi: 10.1111/jocd.70555. Enhancing Facial Rejuvenation Outcomes With a Novel Retinaldehyde-Based Cream: A Comparative Randomized Intra-Individual Study. Monteil C(1), Barreto-Campos V(2), Lain E(3), Guillou E(4), Doat G(4), Nocera T(1). Author info

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study.

15. Lancet Oncol. 2025 Dec;26(12):1598-1611. doi: 10.1016/S1470-2045(25)00543-1. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study. Qin S(1), Gu S(2)

Self-assembled nanoparticles overcoming hypoxic and acidic microenvironment to synergistically potentiate ferroptosis in triple-negative breast cancer.

42. Int J Pharm. 2026 May 5;696:126853. doi: 10.1016/j.ijpharm.2026.126853. Epub 2026 Apr 5. Self-assembled nanoparticles overcoming hypoxic and acidic microenvironment to synergistically potentiate ferroptosis in triple-negative breast cancer. Xu S(1), Gao W(1), Lin S(2), Xu S(3), Shi X(1), Zhe

Usenamine a potentiates anti-CRC activity of sorafenib by inducing autophagy and inhibiting YAP pathway through targeting SOD2.

27. Phytomedicine. 2026 Jun;155:158086. doi: 10.1016/j.phymed.2026.158086. Epub 2026 Mar 14. Usenamine a potentiates anti-CRC activity of sorafenib by inducing autophagy and inhibiting YAP pathway through targeting SOD2. Zhuge W(1), Kuang J(2), Kuang K(2), Rao M(2), Jian D(2), Lin H(2), Li Z(3),

Ferroptosis-sensitizing nanoprodrug system for synergistic therapy of triple-negative breast cancer.

8. J Colloid Interface Sci. 2026 May 15;710:140048. doi: 10.1016/j.jcis.2026.140048. Epub 2026 Feb 3. Ferroptosis-sensitizing nanoprodrug system for synergistic therapy of triple-negative breast cancer. Huang Y(1), Quan T(1), Li B(2), Zhen C(1), Zhang H(1), Li Z(3), Wu C(3), Liang R(4), Sun L(5

Combining sorafenib with spermine and sphingosine synergistically enhances anticancer efficacy by modulating metabolic pathways and gut microbiome in hepatocellular carcinoma.

4. Int J Biol Sci. 2026 Jan 1;22(3):1082-1102. doi: 10.7150/ijbs.118753. eCollection 2026. Combining sorafenib with spermine and sphingosine synergistically enhances anticancer efficacy by modulating metabolic pathways and gut microbiome in hepatocellular carcinoma. Jang HR(1), Kim HJ(1), Kim B

Plasma-activated water as a potential synergist to enhance the insecticidal activity of imidacloprid and flonicamid against cotton aphids.

6. Pest Manag Sci. 2026 May;82(5):4194-4205. doi: 10.1002/ps.70532. Epub 2026 Jan 16. Plasma-activated water as a potential synergist to enhance the insecticidal activity of imidacloprid and flonicamid against cotton aphids. Xu C(#)(1)(2), Han J(#)(1), Chen X(#)(1), Feng J(3), Xu H(1)(2)(4), Cui

Nicotinamide riboside enhances the efficacy of gemcitabine and suppresses PDAC premalignant lesions via SIRT3 activation.

48. Biochem Pharmacol. 2026 Feb;244:117585. doi: 10.1016/j.bcp.2025.117585. Epub 2025 Dec 3. Nicotinamide riboside enhances the efficacy of gemcitabine and suppresses PDAC premalignant lesions via SIRT3 activation. Wu Z(1), Wan Y(1), Liu H(1), Liu J(2), Hu X(3), Meng W(1), Yang X(4), Pu B(5), L

Synergistic effects of niacinamide and low pH on melanin synthesis, melanocyte function and hyperpigmentation: In vitro and clinical insights.

8. Int J Cosmet Sci. 2026 Apr;48(2):445-455. doi: 10.1111/ics.70044. Epub 2025 Nov 30. Synergistic effects of niacinamide and low pH on melanin synthesis, melanocyte function and hyperpigmentation: In vitro and clinical insights. Hakozaki T(1), Laughlin T(1), Zhao W(1), Deng G(2), Wang J(1), Mou

Synergistic antitumor activity of sorafenib and the NUPR1 inhibitor LZX-2-73 in multiple cancer models.

34. Cell Death Dis. 2025 Nov 17;16(1):839. doi: 10.1038/s41419-025-08178-8. Synergistic antitumor activity of sorafenib and the NUPR1 inhibitor LZX-2-73 in multiple cancer models. Liu X(#)(1)(2), Estaras M(#)(1), Cosialls E(1), Peng L(2), Santofimia-Castaño P(3), Iovanna J(4)(5)(6). Author info

Structural characterisation of a polysaccharide from Sanghuangporus vaninii and its synergistic anti-hepatocellular carcinoma activity in combination with sorafenib.

18. Int J Biol Macromol. 2025 Dec;334(Pt 1):148778. doi: 10.1016/j.ijbiomac.2025.148778. Epub 2025 Nov 5. Structural characterisation of a polysaccharide from Sanghuangporus vaninii and its synergistic anti-hepatocellular carcinoma activity in combination with sorafenib. Li J(1), Shi M(1), Jia

Synergistic combination of the adrenergic antagonist SR59230A with common chemotherapeutic drugs and target therapies in cancer and endothelial cells.

13. Invest New Drugs. 2025 Oct;43(5):1166-1176. doi: 10.1007/s10637-025-01587-8. Epub 2025 Oct 18. Synergistic combination of the adrenergic antagonist SR59230A with common chemotherapeutic drugs and target therapies in cancer and endothelial cells. Bandini A(#)(1), Biso L(#)(1), Viaggi C(1), Pa

Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST.

30. Int J Hematol. 2025 Nov;122(5):647-659. doi: 10.1007/s12185-025-04014-z. Epub 2025 May 26. Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST. Takahashi N(1), Kikushige Y(2), Nakamae H(3), Goto T(4), Tomita A(5), Ichii M(6),

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial.

32. Lancet Oncol. 2025 Jun;26(6):719-731. doi: 10.1016/S1470-2045(25)00190-1. Epub 2025 May 8. Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial. Zhou J(1), Bai L(2), Luo J(3), Bai Y(

Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia.

34. Cancer Chemother Pharmacol. 2025 Feb 28;95(1):39. doi: 10.1007/s00280-025-04755-y. Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia. Darstein C(1), Yoon D(2), Yang Y(2), Kapoor S(3), Das

Phase I-IV Drug Trials on Hepatocellular Carcinoma in Asian Populations: A Systematic Review of Ten Years of Studies.

11. Int J Mol Sci. 2024 Aug 27;25(17):9286. doi: 10.3390/ijms25179286. Phase I-IV Drug Trials on Hepatocellular Carcinoma in Asian Populations: A Systematic Review of Ten Years of Studies. Raghav A(1), Jeong GB(1). Author information: (1)Department of Anatomy and Cell Biology, College of Medicin

Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.

50. J Hepatol. 2025 Feb;82(2):258-267. doi: 10.1016/j.jhep.2024.07.017. Epub 2024 Jul 31. Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Lau G(1), Abou-Alfa GK(2), Cheng AL(3), Sukeepaisarnjaroen